Irinotecan is an antineoplastic agent used primarily in the treatment of colorectal cancer. This chemotherapy drug works by inhibiting topoisomerase I, an enzyme essential for DNA replication and cell division. By blocking this enzyme, Irinotecan prevents cancer cells from multiplying, thereby inhibiting tumor growth. It is typically administered in a clinical setting under the supervision of healthcare professionals. Common side effects may include nausea, diarrhea, and fatigue. In summary, Irinotecan is a critical component in the management of colorectal cancer.
Irinotecan exerts its anticancer effects by inhibiting topoisomerase I, preventing DNA replication and leading to the death of rapidly dividing cancer cells.








